Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review

被引：10

作者：

Burlando, Martina ^{[1
]}

Muracchioli, Andrea ^{[1
]}

Cozzani, Emanuele ^{[1
]}

Parodi, Aurora ^{[1
]}

机构：

[1] Univ Genoa, Sect Dermatol, IRCCS, Osped Policlin San Martino, Genoa, Italy

来源：

CASE REPORTS IN DERMATOLOGY | 2021年 / 13卷 / 02期

关键词：

Psoriasis; Vitiligo; Biologic therapy; Narrative review; PATIENT;

D O I：

10.1159/000514198

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing patho-genetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are reported. However, improvements in psoriasis and pre-existing vitiligo after the introduction of biological therapy are also described. To date, anti-TNF-alpha is the most cited group of biological drugs that induce new-onset vitiligo or progression of pre-existence vitiligo in psoriatic patients. Even anti-IL-12/23 class would seem to induce vitiligo (as in our case) or even worse it. Anti-IL-17 drugs induce a progression of pre-existing vitiligo while, to date, no cases are reported in literature considering anti-IL-23 class. (C) 2021 The Author(s). Published by S. Karger AG, Basel

引用

页码：372 / 378

页数：7

共 15 条

[1] AlGhamdi KM, 2012, J DRUGS DERMATOL, V11, P534
[2] Drug-induced vitiligo: a case/non-case study in Vigibase(R), the WHO pharmacovigilance database
Anthony, Norah
Bourneau-martin, Delphine
Ghamrawi, Sarah
Lagarce, Laurence
Babin, Marina
Briet, Marie
[J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (06) : 736 - 742
[3] Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study
Bae, Jung Min
Kim, Miri
Lee, Han Hee
Kim, Ki-Jo
Shin, Hyoseung
Ju, Hyun Jeong
Kim, Gyong Moon
Park, Chul Jong
Park, Hyun Jeong
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (04) : 768 - 774
[4] A Patient with Psoriasis and Vitiligo Treated with Etanercept
Campanati, Anna
Giuliodori, Katia
Ganzetti, Giulia
Liberati, Giulia
Offidani, Anna Maria
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 : 46 - 48
[5] Elkady Amal, 2017, JAAD Case Rep, V3, P477, DOI 10.1016/j.jdcr.2017.07.009
[6] Vitiligo in a patient receiving infliximab for chronic plaque psoriasis
Lu, Xiya
Gao, Yunlu
Ding, Yangfeng
[J]. DERMATOLOGIC THERAPY, 2019, 32 (03)
[7] Masood Sadia, 2014, Oman Med J, V29, P130, DOI 10.5001/omj.2014.31
[8] New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases
Mery-Bossard, L.
Bagny, K.
Chaby, G.
Khemis, A.
Maccari, F.
Marotte, H.
Perrot, J. L.
Reguiai, Z.
Sigal, M. L.
Avenel-Audran, M.
Boye, T.
Grasland, A.
Gillard, J.
Jullien, D.
Toussirot, E.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 181 - 186
[9] Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
Palazzo, Giovanni
[J]. OXFORD MEDICAL CASE REPORTS, 2020, (01): : 13 - 16
[10] Psoriasis and vitiligo
Sandhu, K
Kaur, I
Kumar, B
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : 149 - 150

← 1 2 →